Literature DB >> 20643497

Risk factors for fluoroquinolone resistance in Gram-negative bacilli causing healthcare-acquired urinary tract infections.

P Rattanaumpawan1, P Tolomeo, W B Bilker, N O Fishman, E Lautenbach.   

Abstract

The prevalence of urinary tract infections caused by fluoroquinolone-resistant Gram-negative bacilli (FQ-resistant GNB-UTIs) has been increasing. Previous studies that explored risk factors for FQ resistance have focused only on UTIs caused by Escherichia coli and/or failed to distinguish colonisation from infection. We conducted a case-control study at two medical centres within the University of Pennsylvania Health System to identify risk factors for FQ resistance among healthcare-acquired GNB-UTIs. Subjects with positive urine cultures for GNB and who met Centers for Disease Control and Prevention criteria for healthcare-acquired UTI were eligible. Cases were subjects with FQ-resistant GNB-UTI and controls were subjects with FQ-susceptible GNB-UTI matched to cases by month of isolation and species of infecting organism. In total, 251 cases and 263 controls were included from 1 January 2003 to 31 March 2005. Independent risk factors (adjusted odds ratio; 95% confidence interval) for FQ resistance included male sex (2.03; 1.21-3.39; P=0.007), African-American race (1.80; 1.10-2.94; P=0.020), chronic respiratory disease (2.58; 1.18-5.62; P=0.017), residence in a long term care facility (4.41; 1.79-10.88; P=0.001), hospitalisation within the past two weeks (2.19; 1.31-3.64; P=0.003), hospitalisation under a medical service (2.72; 1.63-4.54; P<0.001), recent FQ exposure (15.73; 6.15-40.26; P<0.001), recent cotrimoxazole exposure (2.49; 1.07-5.79; P=0.033), and recent metronidazole exposure (2.89; 1.48-5.65; P=0.002).
Copyright © 2010 The Hospital Infection Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20643497      PMCID: PMC2962678          DOI: 10.1016/j.jhin.2010.05.023

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  30 in total

1.  Control of a prolonged outbreak of extended-spectrum beta-lactamase-producing enterobacteriaceae in a university hospital.

Authors:  J C Lucet; D Decré; A Fichelle; M L Joly-Guillou; M Pernet; C Deblangy; M J Kosmann; B Régnier
Journal:  Clin Infect Dis       Date:  1999-12       Impact factor: 9.079

2.  Mutational resistance to 4-quinolone antibacterial agents.

Authors:  J T Smith
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

3.  Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections.

Authors:  Ebbing Lautenbach; Neil O Fishman; Warren B Bilker; Analia Castiglioni; Joshua P Metlay; Paul H Edelstein; Brian L Strom
Journal:  Arch Intern Med       Date:  2002-11-25

4.  CDC definitions for nosocomial infections, 1988.

Authors:  J S Garner; W R Jarvis; T G Emori; T C Horan; J M Hughes
Journal:  Am J Infect Control       Date:  1988-06       Impact factor: 2.918

5.  Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

Review 6.  Antimicrobial resistance in long-term-care facilities.

Authors:  L J Strausbaugh; K B Crossley; B A Nurse; L D Thrupp
Journal:  Infect Control Hosp Epidemiol       Date:  1996-02       Impact factor: 3.254

7.  Comparative evaluation of recently developed quinolone compounds--with a note on the frequency of resistant mutants.

Authors:  W Cullmann; M Stieglitz; B Baars; W Opferkuch
Journal:  Chemotherapy       Date:  1985       Impact factor: 2.544

8.  Risk factors for community-acquired ciprofloxacin-resistant Escherichia coli urinary tract infection.

Authors:  Karla M Killgore; Kristi L March; B Joseph Guglielmo
Journal:  Ann Pharmacother       Date:  2004-05-18       Impact factor: 3.154

9.  Risk factors and outcomes associated with isolation of meropenem high-level-resistant Pseudomonas aeruginosa.

Authors:  Kathryn J Eagye; Joseph L Kuti; David P Nicolau
Journal:  Infect Control Hosp Epidemiol       Date:  2009-08       Impact factor: 3.254

10.  Longitudinal trends in fluoroquinolone resistance among Enterobacteriaceae isolates from inpatients and outpatients, 1989-2000: differences in the emergence and epidemiology of resistance across organisms.

Authors:  Ebbing Lautenbach; Brian L Strom; Irving Nachamkin; Warren B Bilker; Ann Marie Marr; Lori A Larosa; Neil O Fishman
Journal:  Clin Infect Dis       Date:  2004-02-17       Impact factor: 9.079

View more
  10 in total

1.  A clinical prediction rule for fluoroquinolone resistance in healthcare-acquired gram-negative urinary tract infection.

Authors:  Pinyo Rattanaumpawan; Pam Tolomeo; Warren B Bilker; Ebbing Lautenbach
Journal:  Infect Control Hosp Epidemiol       Date:  2011-09-29       Impact factor: 3.254

2.  Risk factors for ambulatory urinary tract infections caused by high-MIC fluoroquinolone-susceptible Escherichia coli in women: results from a large case-control study.

Authors:  Pinyo Rattanaumpawan; Irving Nachamkin; Warren B Bilker; Jason A Roy; Joshua P Metlay; Theoklis E Zaoutis; Ebbing Lautenbach
Journal:  J Antimicrob Chemother       Date:  2015-01-27       Impact factor: 5.790

Review 3.  Epidemiological interpretation of studies examining the effect of antibiotic usage on resistance.

Authors:  Vered Schechner; Elizabeth Temkin; Stephan Harbarth; Yehuda Carmeli; Mitchell J Schwaber
Journal:  Clin Microbiol Rev       Date:  2013-04       Impact factor: 26.132

Review 4.  Resistance surveillance studies: a multifaceted problem--the fluoroquinolone example.

Authors:  A Dalhoff
Journal:  Infection       Date:  2012-03-30       Impact factor: 3.553

5.  Risk factors for fluoroquinolone resistance in Enterococcus urinary tract infections in hospitalized patients.

Authors:  P Rattanaumpawan; P Tolomeo; W B Bilker; N O Fishman; E Lautenbach
Journal:  Epidemiol Infect       Date:  2010-08-09       Impact factor: 2.451

6.  An antibiotic prescription induces resistance at the individual level more than the group level.

Authors:  Paul J Drinka; Christopher J Crnich; David A Nace
Journal:  J Am Med Dir Assoc       Date:  2013-06-15       Impact factor: 4.669

7.  Incidence of antibiotic-resistant Escherichia coli bacteriuria according to age and location of onset: a population-based study from Olmsted County, Minnesota.

Authors:  Sanjeev K Swami; Juliette T Liesinger; Nilay Shah; Larry M Baddour; Ritu Banerjee
Journal:  Mayo Clin Proc       Date:  2012-07-13       Impact factor: 7.616

8.  Prevalence and risk factor analysis of resistant Escherichia coli urinary tract infections in the emergency department.

Authors:  Abby M Bailey; Kyle A Weant; Stephanie N Baker
Journal:  Pharm Pract (Granada)       Date:  2013-06-30

9.  Fluoroquinolone resistance among gram-negative urinary tract pathogens: global smart program results, 2009-2010.

Authors:  Sam Bouchillon; Daryl J Hoban; Robert Badal; Stephen Hawser
Journal:  Open Microbiol J       Date:  2012-09-07

10.  Susceptibility pattern of uropathogens to ciprofloxacin at the Ghana police hospital.

Authors:  Daniel Kwame Afriyie; Martha Gyansa-Lutterodt; Seth Kwabena Amponsah; George Asare; Vanessa Wiredu; Edem Wormenor; Kwasi Agyei Bugyei
Journal:  Pan Afr Med J       Date:  2015-10-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.